Lupin gets USFDA nod for generic hypertension drug, Health News, ET HealthWorld


New Delhi: Drug maker Lupin on Sunday said it has received approval from the US health regulator to market a generic hypertension drug in America. The company has received approval from the US Food and Drug Administration (USFDA) for Propranolol Hydrochloride extended-release capsules in multiple strengths, Lupin Ltd said in a regulatory filing.

The company’s product is the generic version of ANI Pharmaceuticals’ Inderal LA extended-release capsules, it added.

The product will be manufactured at the company’s Pithampur-based manufacturing plant, the drug firm stated.

Propranolol Hydrochloride extended-release capsules USP are indicated in the management of hypertension.

They may be used alone or in combination with other antihypertensive agents, particularly a thiazide diuretic.

As per IQVIA MAT November 2023 data, Propranolol Hydrochloride extended-release capsules had estimated annual sales of USD 71 million in the US.

  • Published On Jan 14, 2024 at 04:46 PM IST

Join the community of 2M+ industry professionals

Subscribe to our newsletter to get latest insights & analysis.

Download ETHealthworld App

  • Get Realtime updates
  • Save your favourite articles

Scan to download App


Leave a Reply

Your email address will not be published. Required fields are marked *